Prognostic and predictive roles of KRAS mutation in colorectal cancer

Amanda K. Arrington, Eileen L. Heinrich, Wendy Lee, Marjun Duldulao, Supriya Patel, Julian Sanchez, Julio Garcia-Aguilar, Joseph Kim

Research output: Contribution to journalReview articlepeer-review

161 Scopus citations


The RAS gene family is among the most studied and best characterized of the known cancer-related genes. Of the three human ras isoforms, KRAS is the most frequently altered gene, with mutations occurring in 17%-25% of all cancers. In particular, approximately 30%-40% of colon cancers harbor a KRAS mutation. KRAS mutations in colon cancers have been associated with poorer survival and increased tumor aggressiveness. Additionally, KRAS mutations in colorectal cancer lead to resistance to select treatment strategies. In this review we examine the history of KRAS, its prognostic value in patients with colorectal cancer, and evidence supporting its predictive value in determining appropriate therapies for patients with colorectal cancer.

Original languageEnglish (US)
Pages (from-to)12153-12168
Number of pages16
JournalInternational journal of molecular sciences
Issue number10
StatePublished - Oct 2012


  • Colon cancer
  • Colorectal cancer
  • EGFR
  • KRAS
  • Let7
  • Oncogenes
  • Ras

ASJC Scopus subject areas

  • Catalysis
  • Molecular Biology
  • Spectroscopy
  • Computer Science Applications
  • Physical and Theoretical Chemistry
  • Organic Chemistry
  • Inorganic Chemistry


Dive into the research topics of 'Prognostic and predictive roles of KRAS mutation in colorectal cancer'. Together they form a unique fingerprint.

Cite this